Tuesday, 02. October 2018

PARI Pharma’s eFlow® Technology device, LAMIRA™, approved as the only nebulizer system to deliver Insmed’s ARIKAYCE® (amikacin liposome inhalation suspension).

ARIKAYCE is the First and Only Therapy Specifically Indicated for the Treatment of Mycobacterium Avium Complex (MAC) Lung Disease in Adult Patients...
Friday, 06. April 2018

Sunovion Announces Lonhala™ Magnair™ (glycopyrrolate) Inhalation Solution Now Available in the U.S. for the Treatment of COPD

LONHALA MAGNAIR is the first nebulized long-acting muscarinic antagonist (LAMA) available for the treatment of COPD in the U.S.
Monday, 25. September 2017

ProQR Announces Positive Top-Line Results from a Phase 1b Study of QR-010 in Subjects with Cystic Fibrosis

 

Key updates

  • QR-010 was observed to be safe and well-tolerated across all doses in this trial with no serious adverse events related to treatment.
  • A...

 

Wednesday, 02. November 2016

Sunovion Announces FDA Filing Acceptance of New Drug Application for Sun-101/eFlow® for the Treatment of Patients with Chronic Obstuctive Pulmonary Disease (COPD)

- Sun-101/eflow® (glycopyrrolate) NDA is currently under review; if approved, it would represent the first available nebulized long-acting muscarinic...
Sunovion Submits New Drug Application
Tuesday, 02. August 2016

Sunovion Submits New Drug Application for SUN-101/eFlow® to the FDA

for the Treatment of Patients with Chronic Obstructive Pulmonary Disease (COPD)